What is nilotinib?

Nilotinib is a drug approved by the U.S (FDA) to treat certain types of leukemia. It is considered an investigational drug in NILO-PD because it is not approved to treat Parkinson’s Disease.

Nilotinib inhibits the activity of a protein linked to pathways associated with PD, and preliminary data from a small Phase I clinical trial evaluating the safety and tolerability of nilotinib in Parkinson’s showed potential benefit.